VALN Key Statistics, Chart & Performance
The current stock price of VALN is 8.41 USD. In the past month the price decreased by -11.84%. In the past year, price increased by 94.19%.
VALN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About VALN
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
VALNEVA SE - ADR
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
CEO: Thomas Lingelbach
Employees: 695
Phone: 33228073710
VALNEVA SE - ADR / VALN FAQ
What does VALNEVA SE - ADR do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the stock price of VALNEVA SE - ADR today?
The current stock price of VALN is 8.41 USD. The price decreased by -0.88% in the last trading session.
Does VALNEVA SE - ADR pay dividends?
VALN does not pay a dividend.
What is the ChartMill technical and fundamental rating of VALN stock?
VALN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of VALN stock?
VALNEVA SE - ADR (VALN) has a market capitalization of 722.56M USD. This makes VALN a Small Cap stock.
When does VALNEVA SE - ADR (VALN) report earnings?
VALNEVA SE - ADR (VALN) will report earnings on 2026-03-18, after the market close.
VALN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to VALN. When comparing the yearly performance of all stocks, VALN is one of the better performing stocks in the market, outperforming 91.69% of all stocks.
VALN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VALN. VALN may be in some trouble as it scores bad on both profitability and health.
VALN Financial Highlights
Over the last trailing twelve months VALN reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS decreased by -1180% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| Debt/Equity | 0.8 |
VALN Forecast & Estimates
For the next year, analysts expect an EPS growth of -639.98% and a revenue growth -5.39% for VALN